Skip to main content

Psychometric properties of the Seville quality of life questionnaire in Mexican patients with psychosis



The Seville Quality of Life Questionnaire (CSCV) was designed to assess quality of life in patients with schizophrenia taking into account those facets particularly important in this disorder. The study aimed at applying the CSCV to a sample of Mexican patients with psychosis in an effort further substantiates the psychometric properties of the CSCV.


This cross-sectional study included 61 patients (56 % female) with psychosis. Item-scale and item-factor correlations were analyzed, as well as scale-factor correlations. Cronbach’s Alpha and principal component analysis with varimax rotation were used to assess internal consistency and construct validity, respectively.


Analyses of both, disfavorable and favorable dimensions, showed a stronger item-scale than item-factor correlation, in most cases significant, though. Internal consistency was significant and adequate; higher for scales than for factors. For the disfavorable and the favorable scales 11 and 2 factors were obtained, respectively; explained variance was low.


In this sample of Mexican patients it was replicated that the CSCV is a valid and reliable instrument to assess quality of life in people with psychosis; the use of scale scores is recommended.

Peer Review reports


Paradigms in the assessment of human health have been changing for decades. Human health is currently defined as a state of complete physical, mental and social well-being, rather than the mere absence of disease or illness [1]. Assessment of a patient’s health is no longer based solely on a clinician’s report of the illness, but now includes the patients’ appraisal of their condition as a vital input [2]. An intrinsic element of this new perspective of health is quality of life (QoL), defined as the individuals’ perception of their positions in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns [3]. The concept of QoL is increasingly acknowledged as an important health index and has garnered greater attention in both clinical practice and research.

Growing interest in the study of QoL in the healthcare community has been driven by recognition of health’s subjective dimension, as well as the increasing prevalence of chronic illnesses that require long-term, and in some cases permanent, treatment. Greater numbers of patients now receive adequate treatment that allows them to control their symptoms, and even survive illnesses that were previously treated as terminal. However, this has created the challenge of procuring patient QoL in addition to curing or controlling their ailment [2].

Mental health care must also face this challenge. Traditionally, symptom presence and severity, patient functional status and the adverse effects of medication have been the most widely used outcome metrics in psychiatric care. All are usually reported by clinical staff (psychiatrists, psychologists, nurses, social workers) and/or relatives, supporting the prevailing perspective that self-reporting by psychiatric patients is unreliable [4]. However, advances in both pharmacological and psychotherapeutic treatments have significantly improved patients’ observed clinical status, making them more qualified as informants of the subjective experience of their disorders.

Conceptual and methodological debate is still active in this area [5, 6], but there is growing interest in the study of QoL in psychotic patients [712]. Most studies report on use of generic QoL questionnaires that are useful to a degree, but may not comprehensively reflect the particular experience of schizophrenia when comparing diverse samples (i.e. from the general population or patients with disorders other than psychosis). For schizophrenic patients, QoL depends on myriad factors, including cultural and economic circumstances, societal homogeneity, traditional role of the family, social support, and availability of mental health services [12]. A consistent and negative association has been identified between psychopathology and QoL [7], yet there is no reason to consider the presence of symptoms in psychiatric patients as defining their QoL status. The possible side effects (e.g. lethargy, fatigue) of the antipsychotics used to control positive psychotic symptoms also need to be accounted for since they can negatively impact QoL [13, 14].

In response to this situation, a group of experts in Spain developed the Seville Quality of Life Questionnaire (Cuestionario Sevilla de Calidad de Vida - CSCV) to explore crucial aspects of QoL in schizophrenic patients. Their initial item set consisted of 126 items, but this was reduced to 59 in the final instrument following factorial analyses. The CSCV includes a disfavorable scale (CSCV-D) with 46 items, and a favorable scale (CSCV-F) with 13 items [1316]. Accurate psychometric properties have been reported for this instrument in samples from Spain [15] and Chile [17]. It has been applied in samples from Spain [1821], Chile [2225], Peru [26], and Mexico [27]. Although it is targeted at patients with schizophrenia and related psychosis, it has also been found useful for patients with cases of severe drug addiction [26].

The present study’s aim was to apply the CSCV to a sample of Mexican patients with psychosis in an effort further substantiate the psychometric properties of the CSCV. A reliable and valid instrument is vital to assessing QoL in psychotic patients because it helps to generate dependable research data that can be used to design, implement and evaluate new clinical intervention strategies. Previous studies suggest the CSCV as an effective diagnostic option, particularly, but not limitedly, for Spanish-speaking countries such as Mexico, but its psychometric properties need to be confirmed in target populations before it is applied widely.


Design and participants

Partial data were used from a cross-sectional study on the QoL of psychotic patients and their primary caregivers. The study was done in 2009 at the Yucatan Psychiatric Hospital (Hospital Psiquiátrico Yucatán) in Merida, Mexico. This is the only public institution in the city offering specialized psychiatric care. Following Declaration of Helsinki norms [28], the study protocol was approved by the Bioethics Committee of the host hospital. Patient inclusion criteria were: 1) age at onset 16–45 years; 2) primary current DSM-IV-TR [29] diagnosis of schizophrenia or other schizophrenia spectrum psychotic disorder; and 3) inhabitant of Merida. Exclusion criteria were: 1) a DSM-IV-TR diagnosis of affective, organic, or toxic psychosis [29]; 2) evident intellectual disorder; 3) inadequate contact information; and 4) severe symptomatology impeding patient self-reporting.

A review of clinical files according to these criteria produced 161 potential cases; of which 103 patients could be contacted (55 had moved away or were not home, 3 had died). Five of the remaining candidates were excluded due to severe symptomatology. The final sample included 61 participants (56 % female) who signed an informed consent form including a statement of no economic compensation. None of the participants was hospitalized.

Sample characteristics

Mean age of patients was 35.9 years (SD = 10.0) when interviewed, and 29.1 years (SD = 9.8) at psychosis onset. No differences by sex were observed. Thirty-four (56 %) participants had an education level of middle school or lower (up to 9th grade), and the remaining 27 (44 %) had a partial/complete high school or above education level. The DSM-IV-TR diagnoses for participants were 41 patients with schizophrenia (14 paranoid, 2 disorganized, and 25 residual); and 20 patients with other types of schizophrenia-spectrum psychoses (8 schizoaffective, 7 delusional, 2 schizophreniform, 2 brief, and 1 unspecified). Mean illness course was 6.7 years (SD = 1.9, range 3.8–11.2).

Clinical status was measured using the PANSS (Positive and Negative Syndrome Scale) [30], with possible scores ranging from 1 (absent) to 7 (extreme). Mean scores in the sample were 1.44 (SD = .52) for positive symptoms, 1.67 (SD = .75) for negative symptoms and 1.55 (SD = .42) for the general psychopathology dimension. Mean GAF (Global Assessment of Functioning) [29] score for the sample was 75.3 (SD = 16.5). No differences by sex were identified for any of the PANSS or GAF scores.

Overall mean score for the CSCV-D was 1.71 (SD = .60, range 1.00–3.37), with mean scores for the corresponding nine factors falling within a range of 1.60 to 1.85. Overall mean score for the CSCV-F was 3.05 (SD = .68, range 1.54–4.00), and mean scores for the corresponding three factors ranged from 2.89 to 3.15. No significant differences were identified by sex when comparing the overall CSCV-D and CSCV-F scores, and neither were differences found between any of their corresponding factors.


The CSCV [14, 15] includes 59 Likert scale items, ranging from 1 (totally disagree) to 5 (totally agree). The first 46 items correspond to the CSCV-D scale and are grouped into nine factors; they refer to unpleasant, negative or unsatisfactory aspects (e.g. “I’m bored all the time”, “I’m afraid of myself”, “Everything overwhelms me”). The last 13 items, grouped in three factors, correspond to the CSCV-F scale, and reflect pleasant, positive and satisfactory aspects (e.g. “I like myself”, “I feel comfortable with my thoughts”, “I am capable of organizing my daily life”). The dimensions and their corresponding factors are listed in Table 1. Mean scores can be obtained for the 12 factors and the 2 subscales by averaging their corresponding items. Scores of 1 on the CSCV-D and 5 on the CSCV-F reflect a significantly high quality of life, with eventual psychopathological problems having no or only minimal impact. Conversely, scores of 5 on the CSCV-D and 1 on the CSCV-F represent a patient who estimates his/her QoL as extremely unfavorable or negative, and considers aspects prototypical of good QoL to be absent. A mean CSCV-D score between 3 and 5 identifies patients whose QoL is negatively affected, regardless of their CSCV-F score [13].

Table 1 Item-factor and item-scale Spearman correlations (item included in total score/item excluded in total score)

Statistical analyses

Using the SPSS v.20 statistical package, a series of analyses were run: 1) sample size adequacy (Kaiser-Meyer-Olkin [KMO] index) and data normal distribution (Kolmogorov-Smirnov test, skewness and kurtosis) for each scale; 2) correlations between each item with its corresponding mean factor score and mean scale score; 3) internal consistency of each scale and factor with Cronbach’s α, and with scale-factor correlations; and 4) construct validity, estimating the underlying factors with an exploratory principal component analysis with orthogonal varimax rotation, retaining factors agreeing with Kaiser’s criterion (a.k.a. root latent criterion) (eigenvalue > 1) and items with at least a 0.40 communality value.


Sample size adequacy and normal distribution of data

Kaiser-Meyer-Olkin (KMO) values for sample adequacy were 0.55 for CSCV-D and 0.85 for CSCV-F. KMO statistic varies between 0 (indicating a disperse pattern of correlations; hence, factor analysis would be inappropriate) and 1 (indicating correlations have a rather compressed pattern; thus, factor analysis should yield reliable and definite factors). A minimum of 0.5 is recommended; yet, the closer to 1 the more reliability can be presumed. Mean CSCV-D (D (61) = 0.12, p ≤ .05) and CSCV-F (D (61) = 0.18, p ≤ .001) scores were not normally distributed; kurtosis levels for CSCV-D (z = 0.0331) scores and CSCV-F (z = 0.8212) scores were not significant. Skewness was significant for both scales (CSCV-D, z = 2.91, p ≤ .01; CSCV-F, z = 2.28, p ≤ .05) since participants reported a largely favorable QoL (agreeing mostly with CSCV-F statements and largely disagreeing with CSCV-D statements). In response, four kinds of correlational analyses were run with the Spearman non-parametric test.

Item-factor and item-scale correlations

All item-factor correlations were significant (p < 0.001), as were all item-scale correlations (p < 0.01). When using corrected scores (i.e. item 1 is correlated with the total score obtained with all of its corresponding items but item 1, and so on) correlation values decreased slightly but remained significant (p < 0.05), save for the correlations between items 39, 24, 27 and their corresponding factors (“oddness” and “restrained hostility”). Item-factor correlation values ranged from 0.21 to 0.72, and mean correlation by factor ranged from 0.25 to 0.60.

Item-scale correlation values ranged from 0.33 to 0.77 for CSCV-D and from 0.36 to 0.75 for CSCV-F. Mean item-scale correlations ranged from 0.47 to 0.64 (corrected, from 0.45 to 0.62) for CSCV-D factors and from 0.59 to 0.69 (corrected, from 0.50 to 0.62) for CSCV-F factors. All these correlation values fall within the moderate range (≥ 0.30 and < 0.70). Given that item-scale correlation values were not extreme (rs ≤ 0.30 or rs ≤ 0.90) and all were significant, all original items were included for the subsequent analyses (see summary, Table 1).

Bartlett’s test results were significant (p ≤ 0.001) for both scales and all twelve factors; therefore the items were assumed to be related. In addition, R-matrix determinant values for all factors and the CSCV-F scale ranged from 0.002 to 0.758, thus rejecting multicollinearity (< 0.00001). Given that the items were not excessively related, the factor analysis was continued.

Internal consistency and factor-scale correlations

Alpha (α) values were above 0.80 in both the CSCV-D and CSCV-F scales, suggesting good internal consistency. All twelve factors had an α value above 0.50. CSCV-D α values ranged from 0.576 (“restrained hostility”) to 0.885 (“loss of energy”); mean = 0.728. CSCV-F α values ranged from 0.671 (“self-esteem”) to 0.802 (“vital satisfaction”); mean = 0.742 (Table 2).

Table 2 Internal consistency of scales and factors

Correlation between the CSCV-D and CSCV-F was moderate (−0.57) but significant (p ≤ .001). Correlations below 0.80 were observed between CSCV-D and three of its factors: “restrained hostility” (0.69), “automatisms” (0.68) and “oddness” (0.72). The remaining six factors scored from 0.80 to 0.93. Correlations between CSCV-F and its corresponding factors ranged from 0.86 to 0.93. Correlations between the nine CSCV-D factors varied from 0.43 to 0.81, and between the three CSCV-F factors they ranged from 0.66 to 0.78. All correlations were significant (p ≤ 0.001). A very few significant correlations between a scale and factors of the opposite scale were observed, although the significance level was quite low: between CSCV-D and favorable factors, from −0.46 to–0.56; between CSCV-F and disfavorable factors, from −0.29 and −0.67; favorable and disfavorable factors, from −0.15 and −0.66.

Factor analysis

After rotation, eleven factors met Kaiser’s criterion, explaining 77.4 % of the CSCV-D variance; the first factor explained 9.76 % and the following explained 9.53 %. For variance in the CSCV-F, two factors met the criterion after rotation, explaining 55.1 % of variance; the first factor explained 32.0 % and the next 23.1 %. Loading patterns did not clearly replicate the original nine factors of the CSCV-D or three factors of the CSCV-F (Table 3).

Table 3 Factor loadings for each item onto each factor after rotation


Development of the CSCV was aimed at meeting the need for a tool to assess subjective QoL from the perspective of schizophrenic patients. The present study expands on previous studies of the CSCV’s psychometric properties and replicates its adequacy in a sample of patients from Mexico. Analysis of the CSCV-D and CSCV-F scales showed that the items were more strongly correlated to their scale than to their corresponding factors; however, in almost all cases results were significant. Mean correlations by factor between each scale (CSCV-D and CSCV-F) and its items showed a similar pattern of moderate values.

Internal consistency was significant and satisfactory; it was notably higher in scales than in factors. These results and values are comparable to those previously reported for this instrument with samples from Spain (CSCV-D, α = 0.94; CSCV-F, α = 0.85) [15] and Chile (CSCV-D, α = 0.962; CSCV-F, α = 0.897) [17]. The pattern of factor α values is also comparable to a study done in Chile [17]: CSCV-D from 0.350 (“restrained hostility”) to 0.830 (“loss of energy”), mean = 0.648; CSCV-F from 0.697 (“harmony”) to 0.772 (“vital satisfaction”), mean = 0.732. Given the factor-scale correlations, the disfavorable and favorable scales are clearly differentiated.

Factor analysis results agree with the number of factors obtained in a sample from Chile [17] (CSCV-D: 11, CSCV-F: 2), but differ from those reported in the original study [15] (CSCV-D: 9, CSCV-F: 3). Total explained variance was low (CSCV-D: 77.40 %; CSCV-F: 55.14 %), but higher than reported in previous studies from Spain (CSCV-D: 51.11 %; CSCV-F: 51.32 %) [14] and Chile (CSCV-D: 62.9 %; CSCV-F: 53.5 %) [17].

The psychometric properties of the CSCV in the studied sample of Mexican outpatients with psychosis were effective when considering CSCV-D and CSCV-D scale scoring. Nevertheless, scoring by factors was somewhat problematic, mainly for the factor “restrained hostility”, with two (out of three) non-significant corrected item-factor correlations, a moderate corrected item-scale and a marginal α value. The factor “oddness” had one item (out of three) with a non-significant corrected item-factor correlation and a moderate corrected item-scale, but its α value remained strong. In contrast, the factor “fear of losing control” had moderate correlations with all three of its corresponding items, but a marginal α value. The number of factors and their item loading pattern did not correspond to those reported in the original paper [14], an inconvenience also reported in a study in Chile [17]. The instability of factor structure might have been influenced by the relatively small sample in this study, in comparison to the size of those from Spain (n = 236) [14], and Chile (n = 183) [17]. Although Chilean and Mexican samples yielded equal number of factors for both scales, further analysis comparing factors’ composition was not possible as the necessary data from the former was not available. The CSCV is potentially a very useful QoL assessment tool in psychotic patients, and produces satisfactory psychometric properties. However, the present results suggest that scale scoring is more appropriate than factor scoring in this instrument. Further research is needed to better assess its psychometric properties (particularly its factor construct validity) and its applicability in other (non-Spanish-speaking) populations.

Limiting factors in the present study include its small sample size and use of an exploratory principal component analysis, both of which restrict the ability to generalize from its findings. Also, the KMO values for sample adequacy were acceptable, but low. The results from this sample of Mexican patients with psychosis provide further evidence in favor of the CSCV as an effective QoL assessment instrument in psychotic patients. As with any other assessment tool, caution is needed when applying its specific psychometric features to different populations.


In mental health patients, QoL is now acknowledged as an important factor. Assessing QoL helps in monitoring overall patient status and promotes better patient-staff communication. Patient opinion on their QoL also provides useful information for use in designing and improving clinical services. The CSCV for psychotic patients stands out as a useful tool for this purpose, particularly for mental health professionals in Spanish-speaking countries. The present results support the CSCV as a valid and reliable instrument, although interpretation is best done using scale scores rather than factor scores.


CSCV, Cuestionario Sevilla de Calidad de Vida/Seville Quality of Life Questionnaire; CSCV-D, Seville quality of life questionnaire disfavorable scale; CSCV-F, Seville quality of life questionnaire favorable scale; QoL, quality of life.


  1. 1.

    World Health Organization. WHO definition of health. Accessed 28 Oct 2015.

  2. 2.

    Bullinger M, Quitmann J. Quality of life as patient-reported outcomes: principles of assessment. Dialogues Clin Neurosci. 2014;16:137–45.

    PubMed  PubMed Central  Google Scholar 

  3. 3.

    The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med. 1998;28:551–8.

    Article  Google Scholar 

  4. 4.

    Revicki D, Kleinman L, Cella D. A history of health-related quality of life outcomes in psychiatry. Dialogues Clin Neurosci. 2014;16:127–35.

    PubMed  PubMed Central  Google Scholar 

  5. 5.

    Awad AG, Voruganti LNP. Intervention research in psychosis: Issues related to the assessment of quality of life. Schizophr Bull. 2000;26:557–64.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Renwick L, Lyne J, Owens E, O’ Donoghue B, Madigan K, Turner N, et al. Comparison of generic and disease-specific measures of quality of life in first-episode psychosis. J Psychiatr Res. 2013;47:1403–8.

    Article  PubMed  Google Scholar 

  7. 7.

    Eack SM, Newhill CE. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull. 2007;33:1225–37.

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Malla A, Payne J. First-episode psychosis: psychopathology, quality of life, and functional outcome. Schizophr Bull. 2005;31:650–71.

    Article  PubMed  Google Scholar 

  9. 9.

    Pinikahana J, Happell B, Hope J, Keks NA. Quality of life in schizophrenia: a review of the literature from 1995 to 2000. Int J Ment Health Nurs. 2002;11:103–11.

    Article  PubMed  Google Scholar 

  10. 10.

    Reininghaus U, Priebe S. Measuring patient-reported outcomes in psychosis: conceptual and methodological review. Br J Psychiatry. 2012;201:262–7.

    Article  PubMed  Google Scholar 

  11. 11.

    Katschnig H. Schizophrenia and quality of life. Acta Psychiatr Scand. 2000;407(Suppl):33–7.

    Article  Google Scholar 

  12. 12.

    Alshowkan A, Curtis J, White Y. Quality of life for people with schizophrenia: a literature review. Arab J Psychiatry. 2012;23:122–31.

    Google Scholar 

  13. 13.

    Giner J, Ibáñez E, Franco D, Alarcón RD. Subjectivity in the perception and measurement of quality of life: conceptualization and development of the seville questionnaire. Psychiatr Q. 2008;79:321–30.

    Article  PubMed  Google Scholar 

  14. 14.

    Giner J, Ibañez E, Baca E, Bobes J, Leal C, Cervera S. Desarrollo del Cuestionario Sevilla de Calidad de Vida (CSCV). Actas Luso Esp Neurol Psiquiatr. 1997;25 Suppl 2:11–23.

    Google Scholar 

  15. 15.

    Ibañez E, Giner J, Cervera S, Baca E, Bobes J, Leal C. El Cuestionario Sevilla de Calidad de Vida: Propiedades psicométricas. Actas Luso Esp Neurol Psiquiatr. 1997;25 Suppl 2:24–31.

    Google Scholar 

  16. 16.

    Giner J, Ibáñez E, Cervera S, Leal C, Baca E, Bobes J. Seville quality of life questionnaire: historic outlook of its establishment. Actas Españolas Psiquiatr. 1999;27:8–13.

    CAS  Google Scholar 

  17. 17.

    Alvarado R, Muñoz K. Estudio psicométrico del Cuestionario Sevilla para valorar la calidad de vida en personas con trastornos mentales severos en una muestra Chilena. Rev Chil Neuropsiquiatr. 2006;44:249–57.

    Google Scholar 

  18. 18.

    Poc OG, Ruiz-Iriondo M, Bobowik M. Multi-informant perception of quality of life and adaptation in chronic schizophrenia. Span J Psychol. 2013;16:E106.

    Article  Google Scholar 

  19. 19.

    Giner J, Ibáñez E, Cervera S, Sanmartín A, Caballero R. Subjective experience and quality of life in schizophrenia. Actas Españolas Psiquiatr. 2001;29:233–42.

    CAS  Google Scholar 

  20. 20.

    Giner J, Bobes J, Cervera S, Leal C, Baca E, Ibáñez E. Impact of olanzapine on quality of life of patients with schizophrenia: One-year follow-up with the seville quality of life questionnaire. Actas Españolas Psiquiatr. 2004;32:1–7.

    CAS  Google Scholar 

  21. 21.

    Sañudo-Corrales JI, Herrero-Remuzgo S, Lamas-Bosque F, Franco-Fernández MD. Calidad de vida subjetiva y síntomas psicóticos básicos en pacientes con esquizofrenia en distintos recursos asistenciales: Un estudio preliminar. Anu Psicol clínica y la salud. 2010;6:67–72.

    Google Scholar 

  22. 22.

    Caqueo-Urizar A, Gutierrez-Maldonado J, Ferrer-Garcia M, Morales AU, Fernandez-Davila P. Typology of schizophrenic symptoms and quality of life in patients and their main caregivers in northern Chile. Int J Soc Psychiatry. 2013;59:93–100.

    Article  PubMed  Google Scholar 

  23. 23.

    Caqueo-Urízar A, Gutiérrez-Maldonado J, Ferrer-García M, Fernández-Dávila P. Calidad de vida en pacientes con esquizofrenia de ascendencia étnica Aymara en el norte de Chile. Rev Psiquiatr y Salud Ment. 2012;5:121–6.

    Article  Google Scholar 

  24. 24.

    Caqueo-Urízar A, Lemos-Giráldez S. Calidad de vida y funcionamiento familiar de pacientes con esquizofrenia en una comunidad Latinoamericana. Psicothema. 2008;20:577–82.

    PubMed  Google Scholar 

  25. 25.

    Valdebenito M, Valdebenito M, Cavieres Á. Auto evaluación de personas enfermas de esquizofrenia empleando el Cuestionario Sevilla Calidad de Vida. Rev Chil Neuropsiquiatr. 2008;46:255–62.

    Google Scholar 

  26. 26.

    Lizárraga-Stucchi C, Saba-Barreda C, Terry-Valverde G, Araujo-Cachay L, Agüero-Palacios Y. Eficacia de la memantina en pacientes con daño cerebral por adicción a drogas. Rev Neuropsiquiatr. 2007;70:1–4.

    Google Scholar 

  27. 27.

    Gómez-de-Regil L, Kwapil TR, Barrantes-Vidal N. Illness perception mediates the effect of illness course on the quality of life of Mexican patients with psychosis. Appl Res Qual Life. 2014;9:99–112.

    Article  Google Scholar 

  28. 28.

    World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4.

    Article  Google Scholar 

  29. 29.

    American Psychiatric Association. Diagnostic and statistical manual of mental disorders text revision 4th Ed. Washington, DC: American Psychiatric Association; 2000.

    Google Scholar 

  30. 30.

    Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.

    CAS  Article  PubMed  Google Scholar 

Download references


Author thanks the Consejo Nacional de Ciencia y Tecnología (CONACyT, Mexico) for PhD academic grant (187498), the Hospital Psiquiátrico Yucatán (México) for its support and all who kindly took part as participants.

Availability of data and materials

The dataset supporting the conclusions of this article is included within the article as an additional file. Data that could help identify individuals have been omitted to protect their privacy.

Author’s contributions

LG as the solo author was responsible for protocol and study design, collection and analyses of data, and the present manuscript as it is.

Competing interests

The author declares that she has no competing interests.

Consent to participate

All participants previously signed a written informed consent form including a statement of no economic compensation.

Consent to publish

Not applicable.


The study was performed in accordance with the Declaration of Helsinki and approved by the Bioethics Committee of the “Hospital Psiquiátrico Yucatán”.

Author information



Corresponding author

Correspondence to Lizzette Gómez-de-Regil.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gómez-de-Regil, L. Psychometric properties of the Seville quality of life questionnaire in Mexican patients with psychosis. BMC Psychiatry 16, 160 (2016).

Download citation


  • Seville quality of life questionnaire
  • Schizophrenia
  • Psychosis
  • Quality of life
  • Mexico